Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Quanta Services Inc (PWR) vs BIO-TECHNE Corp (TECH) Price & Performance

Quanta Services IncTrade
BIO-TECHNE CorpTrade

Price performance (Past 24H)

Key statistics

Quanta Services Inc vs BIO-TECHNE Corp — how do they compare? Quanta Services Inc trades at $625.61 (market cap $96.08B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: Quanta Services Inc is far larger — about 8.5× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays the higher dividend (0.44%). Which is the better fit depends on your goals.

PWRTECH
Market Cap
$96.08B$11.34B
Sector
IndustrialsHealth
52-Week High
$785.24$72.48
52-Week Low
$376.01$43.31
Enterprise Value
$102.17B$11.36B
Dividend Yield
0.07%0.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Quanta Services Inc

Quanta Services (PWR) trades at $639.05, up 2.34% with strong technical momentum and bullish sentiment. The stock shows robust fundamentals with revenue growth from $17.1B in 2022 to $28.5B in 2025, supported by a record $53B backlog. Recent Q2 2026 earnings beat expectations with EPS of $4.24 versus $3.31 expected, while analyst consensus remains strongly bullish with a $811.14 price target.

PWR presents compelling growth potential driven by infrastructure demand and AI-related projects, though elevated valuation multiples (P/E 73.12) and significant capital expenditures pose risks. The company's strong backlog and margin expansion support upside, but investors should monitor execution on large-scale projects and competitive pressures in the construction sector.

BIO-TECHNE Corp

Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.

The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Quanta Services Inc

Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.

Read more on PWR

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH